Latest immunotherapy news
.jpg)
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
posted June 5th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Zynyz as First-Line Treatment for Advanced Anal Cancer
posted May 21st
by modernClinician Editorial Team
by modernClinician Editorial Team
.jpg)
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
posted May 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
Peanut Oral Immunotherapy Efficacious in Allergic Adults
posted May 1st
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment Related Articles
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma 
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer Monthly Specialist Briefings
Stay Connected
